HRP20020888B1 - Glikopeptidni fosfonatni derivati - Google Patents

Glikopeptidni fosfonatni derivati

Info

Publication number
HRP20020888B1
HRP20020888B1 HR20020888A HRP20020888A HRP20020888B1 HR P20020888 B1 HRP20020888 B1 HR P20020888B1 HR 20020888 A HR20020888 A HR 20020888A HR P20020888 A HRP20020888 A HR P20020888A HR P20020888 B1 HRP20020888 B1 HR P20020888B1
Authority
HR
Croatia
Prior art keywords
substituted
phosphonate derivatives
glycopeptide
glycopeptide phosphonate
cycloalkenyl
Prior art date
Application number
HR20020888A
Other languages
English (en)
Inventor
R. Leadbetter Michael
S. Linsell Martin
Original Assignee
Theravance
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance filed Critical Theravance
Publication of HRP20020888A2 publication Critical patent/HRP20020888A2/xx
Publication of HRP20020888B1 publication Critical patent/HRP20020888B1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Glikopeptid formule I: naznačen time, da je: R1 je odabran iz skupine koja se sastoji od vodik, alkil, supstituirani alkil, alkenil, supstituirani alkenil, alkinil, supstituirani alkinil, cikloalkil,supstituirani cikloalkil, cikloalkenil, supstituirani cikloalkenil, aril, heteroaril, heterociklik i -Ra -Y-Rb -(Z) ; ili je R1 saharidna skupina neobavezno supstituirana s -Ra-Y-Rb-(Z)x, Rf, -C(O)Rfili
HR20020888A 2000-06-22 2002-11-11 Glikopeptidni fosfonatni derivati HRP20020888B1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (2)

Publication Number Publication Date
HRP20020888A2 HRP20020888A2 (en) 2005-02-28
HRP20020888B1 true HRP20020888B1 (hr) 2007-12-31

Family

ID=22795013

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020888A HRP20020888B1 (hr) 2000-06-22 2002-11-11 Glikopeptidni fosfonatni derivati

Country Status (36)

Country Link
US (10) US6635618B2 (hr)
EP (1) EP1292612B1 (hr)
JP (2) JP3900491B2 (hr)
KR (1) KR100768488B1 (hr)
CN (1) CN100469788C (hr)
AR (1) AR035333A1 (hr)
AT (1) ATE337334T1 (hr)
AU (2) AU2001261107B2 (hr)
BR (1) BRPI0111222B8 (hr)
CA (2) CA2411590C (hr)
CY (2) CY1105194T1 (hr)
CZ (1) CZ303672B6 (hr)
DE (2) DE60122516T2 (hr)
DK (1) DK1292612T3 (hr)
EA (1) EA005953B1 (hr)
EG (1) EG26726A (hr)
ES (1) ES2271012T3 (hr)
HK (1) HK1052191B (hr)
HR (1) HRP20020888B1 (hr)
HU (2) HU229370B1 (hr)
IL (1) IL152408A (hr)
IS (1) IS2303B (hr)
LU (1) LU91908I2 (hr)
MX (1) MXPA02012745A (hr)
MY (1) MY127081A (hr)
NO (2) NO330360B1 (hr)
NZ (1) NZ522279A (hr)
PL (1) PL207101B1 (hr)
PT (1) PT1292612E (hr)
RS (1) RS50499B (hr)
SI (1) SI1292612T1 (hr)
SK (1) SK287470B6 (hr)
TW (1) TWI305209B (hr)
UA (1) UA75083C2 (hr)
WO (1) WO2001098328A2 (hr)
ZA (1) ZA200209419B (hr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1140993T1 (en) * 1998-12-23 2003-12-31 Theravance, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
EP1507796B1 (en) 2002-05-24 2012-05-02 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
AU2003243574A1 (en) 2002-06-17 2003-12-31 Theravance, Inc. PROCESS FOR PREPARING N-PROTECTED Beta-AMINO ALDEHYDE COMPOUNDS
EP1641480A1 (en) * 2003-05-27 2006-04-05 Theravance, Inc. Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent
JP4664912B2 (ja) * 2003-07-22 2011-04-06 セラヴァンス， インコーポレーテッド グリコペプチド抗菌剤と組み合わせたエキノカンジン抗真菌剤の使用
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
CN101395164A (zh) * 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
WO2008077241A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
WO2009061208A1 (en) * 2007-11-09 2009-05-14 Pronova Biopharma Norge As Lipid compounds for use in cosmetic products, as food supplement or as a medicament
EP2238102A4 (en) * 2007-12-26 2011-03-09 Lead Therapeutics Inc NEW HALF-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS
EP2147910A1 (en) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
WO2010048340A2 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
BRPI1014767A2 (pt) 2009-04-28 2016-04-19 Targanta Therapeutics Corp métodos de tratamento de infecções bacterianas usando oritavancina
PT2427415T (pt) 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
US20110009596A1 (en) * 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
UA111475C2 (uk) 2010-11-05 2016-05-10 Пронова Байофарма Нордж Ас Способи лікування із застосуванням ліпідних сполук
WO2013034675A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
EP2753637A1 (en) 2011-09-09 2014-07-16 Sandoz AG Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
EP2961384B1 (en) 2013-02-28 2019-08-28 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
CA2976384A1 (en) 2015-02-23 2016-09-01 Theravance Biopharma Antibiotics Ip, Llc Doses and methods of administering telavancin
CA2983377C (en) 2015-04-28 2023-08-29 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
US20200171124A1 (en) 2016-04-15 2020-06-04 Lupin Limited Topical compositions for ophthalmic and otic use
EP3454883A1 (en) * 2016-05-09 2019-03-20 Xellia Pharmaceuticals ApS Stabilized glycopeptide antibiotic formulations
US20200368312A1 (en) 2017-05-22 2020-11-26 Insmed Incorporated Glycopeptide derivative compounds and uses thereof
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
WO2019111048A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
EP3883589A4 (en) * 2018-11-21 2022-05-25 Insmed Incorporated CLIVABLE LIPO-GLYCOPEPTIDE DERIVATIVES AND THEIR USES

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
NZ236393A (en) 1989-12-13 1992-05-26 Lilly Co Eli N-alkylated glycopeptide derivatives prepared from antibiotics a82846 series and pa-42867-a; pharmaceutical compositions
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
EP0674528A4 (en) 1992-12-02 1996-06-26 Insite Vision Inc DRUG DELIVERY SYSTEM BASED ON CYCLODEXTRIN AND A POLYMER.
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
NZ270387A (en) 1994-01-28 1996-11-26 Lilly Co Eli Glycopeptide antibiotic, its production and compositions thereof
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5614615A (en) 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US6391851B1 (en) * 1997-03-10 2002-05-21 Fujisawa Pharmaceutical Co., Ltd. Hydrochlorides of vancomycin antibiotics and process for producing the same
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
CA2337103A1 (en) * 1998-07-14 2000-01-27 Robert Kerns Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
SI1140993T1 (en) * 1998-12-23 2003-12-31 Theravance, Inc. Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
US6518243B1 (en) 1999-04-02 2003-02-11 Trustees Of Princeton University Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
US6770621B2 (en) 2000-05-02 2004-08-03 Theravance, Inc. Polyacid glycopeptide derivatives
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
MXPA02012670A (es) 2000-06-21 2003-10-06 Cubist Pharm Inc Composiciones y metodos para mejorar la absorcion oral de agentes anti-microbianos.
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
AU2001259302A1 (en) 2000-06-22 2002-01-02 Yongqi Mu Glycopeptide disulfide and thioester derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives

Also Published As

Publication number Publication date
DK1292612T3 (da) 2007-01-02
JP2004501161A (ja) 2004-01-15
MY127081A (en) 2006-11-30
IS2303B (is) 2007-10-15
TWI305209B (en) 2009-01-11
PT1292612E (pt) 2006-12-29
AU6110701A (en) 2002-01-02
HUP0301320A2 (hu) 2003-08-28
WO2001098328A3 (en) 2002-04-11
NO2011025I2 (hr) 2011-11-18
DE60122516D1 (de) 2006-10-05
US20140024604A1 (en) 2014-01-23
AU2001261107B2 (en) 2006-07-20
HU229370B1 (hu) 2013-11-28
RS50499B (sr) 2010-03-02
DE60122516T2 (de) 2007-01-04
ATE337334T1 (de) 2006-09-15
BR0111222A (pt) 2003-04-01
US20070049519A1 (en) 2007-03-01
NO20025954D0 (no) 2002-12-11
WO2001098328A2 (en) 2001-12-27
SK287470B6 (sk) 2010-10-07
CY2012006I1 (el) 2016-06-22
CA2411590A1 (en) 2001-12-27
CZ303672B6 (cs) 2013-02-20
US6872701B2 (en) 2005-03-29
US8859506B2 (en) 2014-10-14
UA75083C2 (uk) 2006-03-15
NZ522279A (en) 2004-07-30
CA2411590C (en) 2010-10-19
KR20030032970A (ko) 2003-04-26
US20060063706A1 (en) 2006-03-23
EP1292612B1 (en) 2006-08-23
BRPI0111222B8 (pt) 2021-05-25
US20020022590A1 (en) 2002-02-21
IS6600A (is) 2002-10-29
US20080312407A1 (en) 2008-12-18
HUP0301320A3 (en) 2007-05-29
EA200300050A1 (ru) 2003-04-24
CY2012006I2 (el) 2016-06-22
US20030207797A1 (en) 2003-11-06
US20100160211A1 (en) 2010-06-24
US20120283195A1 (en) 2012-11-08
SK18522002A3 (sk) 2003-06-03
PL359419A1 (en) 2004-08-23
ZA200209419B (en) 2004-02-19
EA005953B1 (ru) 2005-08-25
IL152408A0 (en) 2003-05-29
CN100469788C (zh) 2009-03-18
US7008923B2 (en) 2006-03-07
CZ20023942A3 (cs) 2003-03-12
PL207101B1 (pl) 2010-11-30
HUS1400024I1 (hu) 2017-03-28
US20050164916A1 (en) 2005-07-28
KR100768488B1 (ko) 2007-10-18
US6887976B2 (en) 2005-05-03
YU96902A (sh) 2006-01-16
NO20025954L (no) 2002-12-11
IL152408A (en) 2009-05-04
US7700550B2 (en) 2010-04-20
EP1292612A2 (en) 2003-03-19
DE122011100062I1 (de) 2012-03-15
US20040063916A1 (en) 2004-04-01
SI1292612T1 (sl) 2006-12-31
CY1105194T1 (el) 2010-03-03
CN1437611A (zh) 2003-08-20
JP3900491B2 (ja) 2007-04-04
US8101575B2 (en) 2012-01-24
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
CA2713965A1 (en) 2001-12-27
HK1052191A1 (en) 2003-09-05
US7351691B2 (en) 2008-04-01
NO2011025I1 (no) 2011-11-18
NO330360B1 (no) 2011-04-04
ES2271012T3 (es) 2007-04-16
EG26726A (en) 2014-06-18
HRP20020888A2 (en) 2005-02-28
MXPA02012745A (es) 2004-04-05
LU91908I2 (fr) 2012-01-30
AR035333A1 (es) 2004-05-12
JP2007045842A (ja) 2007-02-22
HK1052191B (zh) 2007-01-26
BRPI0111222B1 (pt) 2015-03-17
US7208471B2 (en) 2007-04-24

Similar Documents

Publication Publication Date Title
HRP20020888B1 (hr) Glikopeptidni fosfonatni derivati
RS49984B (sr) Inhibitori azot (ii) oksid sintaze
BRPI9914221B8 (pt) derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
CY1107634T1 (el) Φαρμακευτικη συνθεση
HRP20070132T3 (hr) Pirido-7-pirimidin-7-oni supstituirani sa hidroksialkilom
PT1161428E (pt) Compostos de pirimidina
NO20024176D0 (no) Farmasöytiske praparater inneholdende 3-amino- azetidinderivater, de nye derivater og deres fremstilling
SE0000540D0 (sv) New compounds
BR0114045A (pt) Poliarilcarboxamidas úteis como agentes redutores de lipìdeos
YU51400A (sh) Derivati 2-piridilmetilamina, kao korisni fungicidi
GEP20074198B (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
WO2002000650A3 (en) Novel compounds possessing antibacterial, antifungal or antitumor activity
ATE345122T1 (de) Stabile emulsionszubereitungen
HUP0100149A2 (hu) Picorna-vírus-ellenes peptidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2386828A1 (en) Novel pseudoerythromycin derivatives
ES2243579T3 (es) Derivados de pirazolopirideno.
DE60117847D1 (de) Farnesyltransferase hemmende, in der 4-stellung substituierte chinolin- und chinazolinderivate
WO2002024623A3 (en) Novel alkanoic acid derivatives
ES2177058T3 (es) Compuestos eter piperidinilaminometil trifluorometil ciclicos como antagonistas de la sustancia p.
PT1181294E (pt) Novos derivados e analogos da galantamina
PT1157998E (pt) Compostos heterociclicos seus intermediarios e inibidores da elastase
TNSN06142A1 (en) Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
HRP20030797B1 (hr) Fungicidne kompozicije
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
SE9001269D0 (sv) 2-substituted n,n-ditrimethoxybenzoyl piperazines,a preparation process of the same and therapeutic compositions containing them

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20180424

Year of fee payment: 18

PBON Lapse due to non-payment of renewal fee

Effective date: 20190501